{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T10:39:12Z","timestamp":1778323152502,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pilot Feasibility Stud"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of disease ranging from simple fatty liver to non-alcoholic steatohepatitis, cirrhosis, liver cancer and liver failure. NAFLD affects up to 30\u201340% of adults in Western countries and is directly linked to overweight and obesity. There are no approved drugs to specifically target NAFLD, therefore weight loss achieved through changes in dietary and physical activity behaviours is the recommended management approach. However, achieving and sustaining weight loss is challenging for patients with NAFLD. We developed a NAFLD-specific digital lifestyle intervention (VITALISE) to target changes in dietary and physical activity behaviours of patients with NAFLD to initiate weight loss and weight loss maintenance. This study aims to evaluate the feasibility and acceptability of VITALISE in a secondary care clinical setting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A single-centre, one-arm, prospective design will be used to assess the feasibility and acceptability of recruitment, uptake, engagement and completion of VITALISE. Health-related outcomes will be assessed at baseline and 6-months. An interim measure of self-reported weight, physical activity and self-efficacy will be recorded at 12-weeks. Qualitative semi-structured interviews conducted at 6\u00a0months follow up will further explore acceptability and feasibility and fidelity of receipt and enactment. The study aims to recruit 35 patients with newly diagnosed NAFLD over a 6-month time period. Eligible patients will have continuous access to VITALISE and monthly tele-coaching support for 6\u00a0months prior to follow-up with a hepatologist.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>VITALISE offers access to evidence and theory-informed tailored dietary and physical activity support for patients with NAFLD. The intervention is designed for use by patients in their own time, outside of the hospital setting to overcome well documented challenges including attending additional appointments, and lack of time during routine appointments to adequately address lifestyle behaviour change. This feasibility study will determine the feasibility of VITALISE to support clinical care delivery.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ISRCTN12893503.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40814-023-01286-2","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T08:03:33Z","timestamp":1681891413000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Feasibility and acceptability of an evidence-informed digital intervention to support self-management in people with non-alcoholic fatty liver disease: protocol for a non-randomised feasibility study (VITALISE)"],"prefix":"10.1186","volume":"9","author":[{"given":"Leah","family":"Avery","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hollie","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"McPherson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1860-6970","authenticated-orcid":false,"given":"Kate","family":"Hallsworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"issue":"1","key":"1286_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.29466","volume":"67","author":"C Estes","year":"2018","unstructured":"Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123\u201333.","journal-title":"Hepatology"},{"issue":"10083","key":"1286_CR2","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/S0140-6736(16)32234-6","volume":"389","author":"R Williams","year":"2017","unstructured":"Williams R, Alexander G, Aspinall R, Bosanquet J, Camps-Walsh G, Cramp M, et al. New metrics for the lancet standing commission on liver disease in the UK. The Lancet. 2017;389(10083):2053\u201380.","journal-title":"The Lancet"},{"issue":"5","key":"1286_CR3","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","volume":"62","author":"S McPherson","year":"2015","unstructured":"McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management. J Hepatol. 2015;62(5):1148\u201355.","journal-title":"J Hepatol"},{"key":"1286_CR4","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","volume":"10","author":"QM Anstee","year":"2013","unstructured":"Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330\u201344.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"1286_CR5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","volume":"7","author":"N Stefan","year":"2019","unstructured":"Stefan N, H\u00e4ring H-U, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019;7(4):313\u201324.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1286_CR6","first-page":"468","volume":"1","author":"K Hallsworth","year":"2019","unstructured":"Hallsworth K, Adams L. Lifestyle interventions in NAFLD\/NASH: Facts and figures. J Hep Reports. 2019;1:468\u201379.","journal-title":"J Hep Reports"},{"issue":"4","key":"1286_CR7","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","volume":"67","author":"M Romero-G\u00f3mez","year":"2017","unstructured":"Romero-G\u00f3mez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829\u201346.","journal-title":"J Hepatol"},{"issue":"1","key":"1286_CR8","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67(1):328\u201357.","journal-title":"Hepatology"},{"key":"1286_CR9","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL\u2013EASD\u2013EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.\u00a0J Hepatol.\u00a02016;64(6):1388\u2013402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"1286_CR10","unstructured":"NICE. National Institute for Clinical Excellence (NICE) Guidelines: Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49) 2016."},{"key":"1286_CR11","first-page":"15","volume":"2017","author":"L Avery","year":"1968","unstructured":"Avery L, Exley C, McPherson S, Trenell MI, Anstee QM, Hallsworth K. Lifestyle behavior change in patients with nonalcoholic fatty liver disease: a qualitative study of clinical practice. Clin Gastroenterol Hepatol. 1968;2017:15.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1286_CR12","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/tbm\/ibz080","volume":"10","author":"K Hallsworth","year":"2019","unstructured":"Hallsworth K, Dombrowski SU, McPherson S, Anstee QM, Avery L. Using the theoretical domains framework to identify barriers and enabling factors to implementation of guidance for the diagnosis and management of nonalcoholic fatty liver disease: a qualitative study. Transl Behav Med. 2019;10:1016.","journal-title":"Transl Behav Med"},{"issue":"1","key":"1286_CR13","doi-asserted-by":"publisher","first-page":"e000634","DOI":"10.1136\/bmjgast-2021-000634","volume":"8","author":"MA Tincopa","year":"2021","unstructured":"Tincopa MA, Wong J, Fetters M, Lok AS. Patient disease knowledge, attitudes and behaviours related to non-alcoholic fatty liver disease: a qualitative study. BMJ Open Gastroenterol. 2021;8(1):e000634.","journal-title":"BMJ Open Gastroenterol"},{"key":"1286_CR14","volume-title":"Planning health promotion programs: An Intervention Mapping approach: San Francisco","author":"LK Bartholomew","year":"2011","unstructured":"Bartholomew LK, Parcel GS, Kok G, Gottlieb NH, Fern\u00e1ndez M. Planning health promotion programs: An Intervention Mapping approach: San Francisco. CA: Jossey-Bass; 2011."},{"issue":"1","key":"1286_CR15","doi-asserted-by":"publisher","first-page":"e20491","DOI":"10.2196\/20491","volume":"23","author":"K Hallsworth","year":"2021","unstructured":"Hallsworth K, McPherson S, Anstee QM, Flynn D, Haigh L, Avery L. Digital Intervention with lifestyle coach support to target dietary and physical activity behaviors of adults with nonalcoholic fatty liver disease: systematic development process of VITALISE using intervention mapping. J Med Internet Res. 2021;23(1):e20491.","journal-title":"J Med Internet Res"},{"issue":"3","key":"1286_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150205","volume":"11","author":"SM Eldridge","year":"2016","unstructured":"Eldridge SM, Lancaster GA, Campbell MJ, Thabane L, Hopewell S, Coleman CL, et al. Defining feasibility and pilot studies in preparation for randomised controlled trials: development of a conceptual framework. PLoS ONE. 2016;11(3): e0150205.","journal-title":"PLoS ONE"},{"issue":"355","key":"1286_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i5239","volume":"24","author":"SM Eldridge","year":"2016","unstructured":"Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ\u202f: Brit Med J. 2016;24(355): i5239.","journal-title":"BMJ : Brit Med J"},{"issue":"7","key":"1286_CR18","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1136\/flgastro-2020-101480","volume":"12","author":"LJ Neilson","year":"2021","unstructured":"Neilson LJ, Macdougall L, Lee PS, Hardy T, Beaton D, Chandrapalan S, et al. Implementation of a care bundle improves the management of patients with non-alcoholic fatty liver disease. Frontline Gastroenterol. 2021;12(7):578\u201385.","journal-title":"Frontline Gastroenterol"},{"key":"1286_CR19","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/1745-6215-15-264","volume":"15","author":"MD Teare","year":"2014","unstructured":"Teare MD, Dimairo M, Shephard N, Hayman A, Whitehead A, Walters SJ. Sample size requirements to estimate key design parameters from external pilot randomised controlled trials: a simulation study. Trials. 2014;15:264.","journal-title":"Trials"},{"key":"1286_CR20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12874-015-0045-7","volume":"15","author":"S Amireault","year":"2015","unstructured":"Amireault S, Godin G, Lacombe J, Sabiston CM. The use of the Godin-Shephard leisure-time physical activity questionnaire in oncology research: a systematic review. BMC Med Res Methodol. 2015;15:60.","journal-title":"BMC Med Res Methodol"},{"issue":"4 Pt 1","key":"1286_CR21","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1111\/j.1475-6773.2004.00269.x","volume":"39","author":"JH Hibbard","year":"2004","unstructured":"Hibbard JH, Stockard J, Mahoney ER, Tusler M. Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res. 2004;39(4 Pt 1):1005\u201326.","journal-title":"Health Serv Res"},{"issue":"4","key":"1286_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21040","volume":"21","author":"P Little","year":"2017","unstructured":"Little P, Stuart B, Hobbs FDR, Kelly J, Smith E, Bradbury K, et al. Randomised controlled trial and economic analysis of an internet-based weight management programme: POWeR+ (Positive Online Weight Reduction). Health Technol Assess. 2017;21(4):1\u201362.","journal-title":"Health Technol Assess"},{"key":"1286_CR23","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3389\/fphys.2016.00681","volume":"7","author":"AM Leinonen","year":"2017","unstructured":"Leinonen AM, Ahola R, Kulmala J, Hakonen H, V\u00e4h\u00e4-Ypy\u00e4 H, Auvinen J, et al. Measuring physical activity in free-living conditions\u2014comparison of three accelerometry-based methods. Front Physiol. 2017;7:681.","journal-title":"Front Physiol"},{"key":"1286_CR24","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1097\/00005768-199805000-00021","volume":"30","author":"PS Freedson","year":"1998","unstructured":"Freedson PS, Melanson E, Sirard J. Calibration of the computer science and applications Inc accelerometer. Med Sci Sports Exerc. 1998;30:777\u201381.","journal-title":"Med Sci Sports Exerc"},{"issue":"2","key":"1286_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qual Res Psychol"}],"container-title":["Pilot and Feasibility Studies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40814-023-01286-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40814-023-01286-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40814-023-01286-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T08:08:41Z","timestamp":1681891721000},"score":1,"resource":{"primary":{"URL":"https:\/\/pilotfeasibilitystudies.biomedcentral.com\/articles\/10.1186\/s40814-023-01286-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1286"],"URL":"https:\/\/doi.org\/10.1186\/s40814-023-01286-2","relation":{},"ISSN":["2055-5784"],"issn-type":[{"value":"2055-5784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,19]]},"assertion":[{"value":"18 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"An independent NHS Research Ethics Committee (North East\u2014Tyne & Wear South Research Ethics Committee) has ethically approved the study (IRAS ID: 313662). Patients will provide written informed consent prior to participating in this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}